Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
FP14 - Targeted Therapy - Clinically Focused
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Targeted Therapy - Clinically Focused
-
+
FP14.05 - LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).
00:00 - 00:00 | Presenter: Koichi Goto
- Abstract
Loading... -
+
FP14.07 - Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions
00:00 - 00:00 | Presenter: Julia K Rotow
- Abstract
Loading...
-
+
P86 - Targeted Therapy - Clinically Focused - New Target
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P86.08 - Phase 2 Study of Zenocutuzumab (MCLA-128), a Bispecific HER2/HER3 Antibody in NRG1 Fusion-Positive Advanced Solid Tumors
00:00 - 00:00 | Presenter: Alison M Schram
- Abstract
Loading...
-
+
MA11 - Expanding Targetable Genetic Alterations in NSCLC
- 14:15 - 15:15
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Targeted Therapy - Clinically Focused
-
+
MA11.07 - Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors
14:35 - 14:40 | Presenter: Byoung Chul Cho
- Abstract
Loading... -
+
MA11.09 - Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer
14:45 - 14:50 | Presenter: Daniel SW Tan
- Abstract
Loading...
-
+
ES30 - What is the Best Treatment Strategy to Target Rare Mutations
- 16:45 - 17:45
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Targeted Therapy - Clinically Focused
-
+
ES30.03 - Multiple Generations of TKIs Which Target the ErbB Receptors
16:45 - 16:57 | Presenter: Alexander Drilon
- Abstract
No abstract available for this presentation